This inventor holds 1 USPTO granted patent. Top assignees: Boston University, Universita Di Perugia. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2019
Title: Emiliano Biasini: Innovator in Neurodegenerative Disorder Treatments
Introduction
Emiliano Biasini is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of neurodegenerative disorders through his innovative research and patent.
Latest Patents
Emiliano Biasini holds a patent for "Prion protein ligands as therapeutic agents for neurodegenerative disorders." This invention provides compositions and methods for the treatment of neurodegenerative diseases, particularly those associated with protein aggregation. The invention is based on the discovery of binding regions on the surface of PrPc, known as PrPc Binding Domains (PBD). The inventors have identified six different binding regions on PrPc, referred to as PBD-1 through PBD-6. Each of these domains is defined by a cluster of amino acids located in the globular domain of the protein, specifically in the C-terminal half of the protein, which includes residues 120-230. One embodiment of the invention utilizes residues 127-226.
Career Highlights
Throughout his career, Emiliano Biasini has worked with prestigious institutions, including Boston University and Università di Perugia. His research has focused on developing therapeutic agents that target prion proteins, which are crucial in the study of neurodegenerative diseases.
Collaborations
Emiliano has collaborated with notable colleagues such as David A. Harris and Aaron Beaty Beeler. Their combined expertise has contributed to advancements in understanding and treating neurodegenerative disorders.
Conclusion
Emiliano Biasini's work in the field of neurodegenerative disorders highlights the importance of innovative research in developing effective treatments. His patent and collaborations reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile